Drug-Induced Liver Injury: 5 Things to Know
Nancy S. Reau, MD
March 07, 2019
Did you know that most acute liver failure is caused by drugs?[1] While rare, drug-induced liver injury (DILI) is the leading reason for a medication approved by the US Food and Drug Administration to subsequently be withdrawn from the market.[2,3] This frightening complication can result from both prescribed and over-the-counter agents, including some herbal and dietary supplements.
DILI is both difficult to predict and challenging to recognize. Considering that the range of presentations can also be bewildering—from mild asymptomatic liver test abnormalities to acute hepatic failure—here are five issues to be aware of related to DILI.
1. Some patterns are safer than others; recognize Hy's Law.
Although hepatocellular or cholestatic injuries alone rarely lead to transplantation or death, jaundice (bilirubin > 2 times upper limit of normal) in combination with elevated serum aminotransferase levels (> 3 times upper limit of normal) has the worst prognosis. These findings in a patient with a hepatocellular pattern of injury are associated with mortality rates as high as 10%-50% without transplantation.[4,5] This pattern was first identified by Hyman Zimmerman and is now called Hy's Law.
Categorizing DILI into one of its three basic injury patterns—hepatocellular, cholestatic, and mixed hepatocellular-cholestatic—may not be granular enough to fully characterize the injury, though. Therefore, a clinical phenotype is also used and is based on multiple elements.
Twelve distinct DILI phenotypes have been described and include parallels to known liver injuries, such as acute
hepatitis, autoimmune hepatitis, and
cholangitis. While not all patients will fit neatly into a single phenotype, characterizing the type of DILI is important for both diagnosis and prognosis.
2. Acetaminophen remains the leading cause of DILI, but only half of cases are from intentional overdose.
Acetaminophen is added to hundreds of prescription and over-the-counter medications. While safe when used as directed, it remains the most common drug implicated in acute DILI and is also the leading cause of acute liver failure.[6]
Only half of acute liver failure cases are from intentional overdoses of acetaminophen; the other half occur from chronic use or unintentional overdoses. This is very important, as there are substantial differences in the evaluation and prognosis of these patients. The
Rumack-Matthew nomogram is used to estimate probable hepatic toxicity after a single ingestion; however, because its use is obsolete in chronic, ongoing therapeutic misadventures, the efficacy of
N-acetylcysteine cannot be predicted using the same
rules.
Long-term use of supratherapeutic amounts is more toxic and recognized later than a single ingestion; therefore, these patients have higher rates of severe hepatotoxicity, liver-related complications, and death, as compared to those who have attempted
suicide with acetaminophen. Most patients with acetaminophen-induced acute liver injury present with undetectable levels of acetaminophen, and this is especially true for those with accidental overdoses.[7] Therefore, clinicians need to consider acetaminophen as an explanation for acute liver failure, even when the history and the blood level of acetaminophen are not supportive.
3. Alcohol ingestion has a surprising relationship with acetaminophen.
Contrary to what one might think about alcohol being a risk factor for hepatotoxicity, ingesting alcohol and
acetaminophen together does not increase the risk for hepatotoxicity due to the acetaminophen. In fact, the rate of liver injury was found to be substantially lower (5.1% vs 15.2%) in those who had an acute acetaminophen overdose with alcohol ingestion compared with acetaminophen alone.[8] Alcohol, as a substrate of CYP2E1, may lower the risk for liver injury by competing with acetaminophen for the enzymes, thus decreasing the amount of the toxic metabolite produced. The role of chronic alcohol ingestion is controversial, especially when those with an
alcohol use disorder stay within the therapeutic recommendations for acetaminophen. Still, most clinicians recommend a lower daily dose of acetaminophen for these patients, as repeated supratherapeutic doses of acetaminophen are well recognized to increase the risk for hepatotoxicity.[9]
Patients with advanced liver disease should also limit their acetaminophen intake.[8]
Cirrhosis, regardless of the etiology, reduces the metabolism of acetaminophen.
Therefore, given the potential risk, patients with either an alcohol use disorder or underlying liver disease should be advised to limit their daily amount of acetaminophen to less than 2 g/day.
4. Risk for DILI from statins may be overestimated.
Clinicians may be hesitant to prescribe statins to patients with liver disease and thus miss an important opportunity to reduce
cardiovascular risk. This is especially true in conditions like nonalcoholic
fatty liver disease (NAFLD), where cardiovascular disease is the leading cause of mortality.
Mild to moderate transient asymptomatic elevations in serum aminotransferase levels are common with statins. This phenomenon occurs early after the initiation of therapy but eventually normalizes, despite ongoing therapy.[10] So, this is a lab abnormality and not a true liver injury; liver biopsy shows no histopathologic change.
According to the
Drug-Induced Liver Injury Network (DILIN), only 3.4% of reported drug-induced liver injuries were linked to statins, confirming its rare occurrence.[11] Growing evidence also shows that statins may actually reduce the risk for liver cancer and improve outcomes in those diagnosed with
hepatocellular carcinoma.[12] Although we do not recommend starting a statin to reduce the risk for liver cancer, clinicians should not be afraid to use this class of agents to reduce the risk for cardiovascular disease.